CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03680781
NCT03680781N/ACompleted
CompareCT.gov

Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study

Stanford University·interventional·Posted Sep 21, 2018·Updated Apr 21, 2026

In Brief

A clinical study evaluating Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFC and Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFC for Treatment Resistant Depression. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment Resistant Depression
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 21, 2018
Enrollment StartApr 13, 2018
Primary CompletionDec 2, 2024
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 7.8 years ago

Interventions

Intermittent theta-burst stimulation (iTBS) delivered to the L-DLPFCdevice

Participants will receive iTBS to the left DLPFC and will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004). Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device.

Intermittent theta-burst stimulation (iTBS) delivered to the bilateral DLPFCdevice

Participants will receive iTBS to bilateral DLPFC. The DLPFC will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004). Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device.